Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.75 |
| ▸ | PDE3B | Q13370 | 8/20 | 0.75 |
| ▸ | PDE3A | Q14432 | 8/20 | 0.75 |
| ▸ | NQO2 | P16083 | 2/20 | 0.75 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.75 |
| ▸ | ABL1 | P00519 | 1/20 | 0.75 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.75 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.75 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.75 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.75 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.75 |
| ▸ | PDE2A | O00408 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE1A | P54750 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.47 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4252065 | 0.87 | MET (0.77) | METPDE3BPDE3ANQO2PIP4K2C | |
| SCHEMBL15177004 | 0.86 | MET (0.70) | METPDE3BPDE3ANQO2PIP4K2C | |
| SCHEMBL4499219 | 0.86 | MET (0.76) | METPDE3BPDE3ANQO2PIP4K2C | |
| SCHEMBL15177005 | 0.86 | MET (0.76) | METPDE3BPDE3ANQO2PIP4K2C | |
| Sgx-523 SCHEMBL30222396 | 0.86 | MET (1.00) | METPDE3BPDE3ANQO2PIP4K2C | |
| Sgx-523 SCHEMBL4496422 | 0.86 | MET (1.00) | METPDE3BPDE3ANQO2PIP4K2C | |
| Sgx-523 SCHEMBL29354539 | 0.86 | MET (1.00) | METPDE3BPDE3ANQO2PIP4K2C | |
| SCHEMBL4255231 | 0.85 | MET (0.75) | METPDE3BPDE3ANQO2PIP4K2C | |
| SCHEMBL4255545 | 0.85 | MET (0.75) | METPDE3BPDE3ANQO2PIP4K2C | |
| SCHEMBL4509238 | 0.84 | MET (0.68) | METPDE3BPDE3ANQO2PIP4K2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260531-B2 | Anti-c-met antibodies | ELI LILLY AND COMPANY (US) | 2016-02-16 | — | — | US | claimed |
| US-20150118238-A1 | Anti-c-Met Antibodies | ELI LILLY AND COMPANY | 2015-04-30 | — | — | US | claimed |
| EP-2870178-B1 | ANTI-C-MET ANTIBODIES | LILLY CO ELI (US) | 2017-07-12 | — | — | EP | disclosed |
| EP-2870178-B1 | ANTI-C-MET ANTIBODIES | LILLY CO ELI (US) | 2017-07-12 | — | — | EP | disclosed |
| US-9695175-B2 | Highly selective c-Met inhibitors as anticancer agents | CB THERAPEUTICS INC. (KY) | 2017-07-04 | — | — | US | disclosed |
| US-9260531-B2 | Anti-c-met antibodies | ELI LILLY AND COMPANY (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260531-B2 | Anti-c-met antibodies | ELI LILLY AND COMPANY (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260531-B2 | Anti-c-met antibodies | ELI LILLY AND COMPANY (US) | 2016-02-16 | — | — | US | disclosed |
| US-9201074-B2 | Anti-c-Met antibodies | ELI LILLY AND COMPANY (US) | 2015-12-01 | — | — | US | disclosed |
| US-9201074-B2 | Anti-c-Met antibodies | ELI LILLY AND COMPANY (US) | 2015-12-01 | — | — | US | disclosed |
| US-9201074-B2 | Anti-c-Met antibodies | ELI LILLY AND COMPANY (US) | 2015-12-01 | — | — | US | disclosed |
| WO-2013043452-A1 | ANTI-C-MET ANTIBODIES | ELI LILLY AND COMPANY (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2012015677-A9 | 6-(1-METHYL-1H-PYRAZOL-4-YL)-3-(2-METHYL-2H-INDAZOL-5-YLTHIO)-[1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE AS A C-MET INHIBITOR | ELI LILLY AND COMPANY (US) | 2012-12-13 | — | — | WO | disclosed |
| US-8268836-B2 | Compound useful as a c-Met inhibitor | ELI LILLY AND COMPANY (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268836-B2 | Compound useful as a c-Met inhibitor | ELI LILLY AND COMPANY (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268836-B2 | Compound useful as a c-Met inhibitor | ELI LILLY AND COMPANY (US) | 2012-09-18 | — | — | US | disclosed |
| WO-2012015677-A1 | 6- (1-METHYL-1H-PYRAZOL-4-YL)-3-(2-METHYL-2H-INDAZOL-5- | ELI LILLY AND COMPANY (US) | 2012-02-02 | — | — | WO | disclosed |
| US-20120028984-A1 | Compound Useful As A c-MET Inhibitor | ELI LILLY AND COMPANY (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028984-A1 | Compound Useful As A c-MET Inhibitor | ELI LILLY AND COMPANY (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028984-A1 | Compound Useful As A c-MET Inhibitor | ELI LILLY AND COMPANY (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150118238-A1 | Anti-c-Met Antibodies | MET, HGF, HGFAC | MET 1/4885PDE3B 4365/4885PDE3A 4488/4885 |
| US-20120028984-A1 | Compound Useful As A c-MET Inhibitor | MET, HGF, HGFAC | MET 1/4885PDE3B 2961/4885PDE3A 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.